通过调节阿斯巴酸β-基酶,高水平的2-格卢酸在胆管癌化疗中对抗DNA损伤反应
Katsuya Nagaoka1, Xuewei Bai2, Dan Liu2
1Liver Research Center, Rhode Island Hospital and the Alpert Medical School of Brown University, Providence, RI, USA; Department of Gastroenterology & Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Cancer letters
|November 17, 2023
概括
升高的2-氧格酸盐 (2-OG) 和阿斯巴酸β-化酶 (ASPH) 通过抑制DNA损伤反应 (DDRs) 来促进胆管癌 (CCA) 的化学抵抗. 向ASPH可以提高CCA中的化疗疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 胆管癌 (CCA) 对常规化疗具有抗性,通常与DNA损伤反应 (DDR) 途径有关.
- 在DDR中2-oxoglutarate (2-OG) 依赖的二氧化原酶的作用及其对CCA化学抵抗的影响尚未完全理解.
研究的目的:
- 调查CCA患者血清2-OG水平与化疗结果之间的关联.
- 阐明2-OG和阿斯巴酸β-基酶 (ASPH) 影响CCA中的DDR和化学抵抗的机制.
主要方法:
- 在化疗前,测量了CCA患者的血清2-OG水平.
- 用2-OG治疗了CCA细胞系,并且操纵了ASPH表达 (过度表达和淘汰).
- 用小分子抑制剂向ASPH对化疗反应和DDR调节器 (ATM,ATR) 的影响在体外和临床前CCA模型中进行了评估.
主要成果:
- 与患有稳定疾病 (SD) 或部分反应 (PR) 的患者相比,在患有进展性疾病 (PD) 的CCA患者中观察到较高的血清2-OG水平.
- 外源的2-OG和ASPH过度表达减少了CCA细胞中的DDR,而ASPH敲击增强了化疗敏感性.
- 用抑制剂向ASPH通过调节ATM和ATR信号来提高CCA模型中的化疗疗效.
结论:
- 增加的2-OG和ASPH通过对抗DDR通路,有助于CCA化学抵抗.
- 向ASPH是一个有前途的治疗策略,可以增强DNA损伤反应并改善胆管癌的化疗结果.
相关概念视频
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Allosteric Proteins-ATCase
5.8K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K


